Understand the source comparison
DSIP Half Life: Peptide Comparison
Understanding how DSIP's pharmacokinetic profile compares to other commonly researched peptides clarifies why dosing strategies differ so dramatically across peptide classes. And why applying GLP-1 dosing logic to DSIP would be a fundamental error. DSIP 7–15 m
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Understanding how DSIP's pharmacokinetic profile compares to other commonly researched peptides clarifies why dosing strategies differ so dramatically across peptide classes. And why applying GLP-1 dosing logic to DSIP would be a fundamental error.
- DSIP
- 7–15 minutes
- Receptor-mediated signaling cascade (sleep architecture, HPA axis modulation)
- Once daily to once weekly
- Dosing interval determined by cascade duration and receptor resensitization, NOT plasma clearance
- Semaglutide
- ~7 days
- Continuous GLP-1 receptor agonism (appetite suppression, gastric emptying)
- Once weekly
- Dosing interval directly tied to half-life. Requires sustained plasma levels to maintain effect
- BPC-157
- ~4 hours (estimated)
- Tissue repair signaling, angiogenesis promotion
- Once or twice daily
- Moderate half-life allows once-daily dosing; effects are cumulative over multi-day protocols
- Ipamorelin
- ~2 hours
- Growth hormone secretagogue receptor (GHSR) agonist
- 1–3 times daily
- Pulsatile GH release requires dosing aligned with natural GH peaks (morning, post-workout, pre-sleep)
- TB-500 (Thymosin Beta-4)
- Actin sequestration, cell migration signaling
- Twice weekly
- Long tissue residence time and cumulative signaling allow infrequent dosing despite short plasma half-life
- Melanotan II
- ~33 minutes
- Melanocortin receptor agonist (pigmentation, libido)
- Daily to every other day
- Effects accumulate over days; daily dosing maintains receptor occupancy during loading phase
- The bottom line: peptides with identical half-lives can require radically different dosing schedules depending on whether their mechanism depends on continuous receptor occupancy (like semaglutide) or transient signaling initiation (like DSIP). The DSIP half life of 7–15 minutes is pharmacologically irrelevant to study design. What matters is the 90–180 minute cascade duration and the 48–72 hour system reset time. Researchers who dose DSIP multiple times per day because "it clears fast" are misunderstanding the entire mechanism.